BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for its other major products. The company’s half-year profit rose sharply thanks to a one-time gain.
Hutchmed reported revenue of $277.7 million yuan for the six-month period, down 9% from the $305.7 million yuan it generated a year earlier, according to its results released last Thursday. Revenue from the company’s sales of Fruzaqla, its best-selling drug for treatment of colorectal cancer, rose 1% year-on-year to $43 million in the first half of the year. But that wasn’t enough to offset declines of 27% to 50% for its next three best-selling drugs.
The company’s net income jumped to $455 million in the first half of the year from $25.8 million a year earlier, benefiting from a $477 million one-time gain on disposal of an asset.
Hutchmed’s New York-listed stock fell 16.3% in the two trading days after the announcement to close last Friday at $15. The stock is up 4.5% this year.
By Doug Young
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: SICC launches $260 million IPO
BRIEF: CATL halts lithium production at Jiangxi mine
RELATED ARTICLES
-
BRIEF: Hutchmed profit falls on shrinking R&D income
0013.HK HCM.US -
BRIEF: Boyaa profit falls up to 35% in first half of 2025
0434.HK
-
BRIEF: San Miguel records revenue, profit growth in first half of 2025
0236.HK
-
BRIEF: MicroPort ‘s revenue soars in first half of 2025
2252.HK
-
BRIEF: WuXi XDC’s profit jumps in first half of 2025
2268.HK
-
BRIEF: Zibuyu’s profit rises more than 30% in first half of 2025
2420.HK
-
BRIEF: Miniso’s revenue rises, but profit falls as same-store sales remain weak
9896.HK MNSO.US
